Janux Therapeutics reported financial results for the three and six months ended June 30, 2026. The company held $970.9 million in cash, cash equivalents, and short-term investments as of June 30, 2026. Research and development expenses were $31.0 million for the quarter, compared to $34.7 million in the prior year period. General and administrative expenses totaled $11.0 million, up from $10.5 million. The net loss was $22.0 million for the quarter, a decrease from $33.9 million in the comparable 2025 period. Clinically, JANX007 enrollment continues in taxane-naïve monotherapy and darolutamide combination cohorts, while JANX014 Phase 1 enrollment is ongoing. JANX011 healthy volunteer studies are progressing as planned, with initial data expected in the second half of 2026. JANX013 remains on track for clinical initiation later this year. Janux Therapeutics operates in the biopharmaceutical industry, developing novel immunotherapies.

William Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc. on June 23, 2026, in a termination without "Cause" under the terms of a severance benefit plan. The Company is searching for a successor and interim responsibilities will be assumed by the existing clinical leadership team. Janux Therapeutics, Inc. is a biotechnology company focused on developing cell therapies.